Luana Cristina Camargo, Ian Gering, Mohammadamin Mastalipour, Victoria Kraemer-Schulien, Tuyen Bujnicki, Dieter Willbold, Mônika A. Coronado* and Raphael J. Eberle*,
{"title":"一种蛇毒多肽及其衍生物可防止 Aβ42 聚合并消除体外毒性 Aβ42 聚合体","authors":"Luana Cristina Camargo, Ian Gering, Mohammadamin Mastalipour, Victoria Kraemer-Schulien, Tuyen Bujnicki, Dieter Willbold, Mônika A. Coronado* and Raphael J. Eberle*, ","doi":"10.1021/acschemneuro.4c00089","DOIUrl":null,"url":null,"abstract":"<p >Over a century has passed since Alois Alzheimer first described Alzheimer’s disease (AD), and since then, researchers have made significant strides in understanding its pathology. One key feature of AD is the presence of amyloid-β (Aβ) peptides, which form amyloid plaques, and therefore, it is a primary target for treatment studies. Naturally occurring peptides have garnered attention for their potential pharmacological benefits, particularly in the central nervous system. In this study, nine peptide derivatives of Crotamine, a polypeptide from <i>Crotalus durissus terrificus</i> Rattlesnake venom, as well as one <span>d</span>-enantiomer, were evaluated for their ability to modulate Aβ<sub>42</sub> aggregation through various assays such as ThT, QIAD, SPR, and sFIDA. All tested peptides were able to decrease Aβ<sub>42</sub> aggregation and eliminate Aβ<sub>42</sub> aggregates. Additionally, all of the peptides showed an affinity for Aβ<sub>42</sub>. This study is the first to describe the potential of crotamine derivative peptides against Aβ<sub>42</sub> aggregation and to identify a promising <span>d</span>-peptide that could be used as an effective pharmacological tool against AD in the future.</p>","PeriodicalId":13,"journal":{"name":"ACS Chemical Neuroscience","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acschemneuro.4c00089","citationCount":"0","resultStr":"{\"title\":\"A Snake Venom Peptide and Its Derivatives Prevent Aβ42 Aggregation and Eliminate Toxic Aβ42 Aggregates In Vitro\",\"authors\":\"Luana Cristina Camargo, Ian Gering, Mohammadamin Mastalipour, Victoria Kraemer-Schulien, Tuyen Bujnicki, Dieter Willbold, Mônika A. Coronado* and Raphael J. Eberle*, \",\"doi\":\"10.1021/acschemneuro.4c00089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Over a century has passed since Alois Alzheimer first described Alzheimer’s disease (AD), and since then, researchers have made significant strides in understanding its pathology. One key feature of AD is the presence of amyloid-β (Aβ) peptides, which form amyloid plaques, and therefore, it is a primary target for treatment studies. Naturally occurring peptides have garnered attention for their potential pharmacological benefits, particularly in the central nervous system. In this study, nine peptide derivatives of Crotamine, a polypeptide from <i>Crotalus durissus terrificus</i> Rattlesnake venom, as well as one <span>d</span>-enantiomer, were evaluated for their ability to modulate Aβ<sub>42</sub> aggregation through various assays such as ThT, QIAD, SPR, and sFIDA. All tested peptides were able to decrease Aβ<sub>42</sub> aggregation and eliminate Aβ<sub>42</sub> aggregates. Additionally, all of the peptides showed an affinity for Aβ<sub>42</sub>. This study is the first to describe the potential of crotamine derivative peptides against Aβ<sub>42</sub> aggregation and to identify a promising <span>d</span>-peptide that could be used as an effective pharmacological tool against AD in the future.</p>\",\"PeriodicalId\":13,\"journal\":{\"name\":\"ACS Chemical Neuroscience\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.acs.org/doi/epdf/10.1021/acschemneuro.4c00089\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Chemical Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acschemneuro.4c00089\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Chemical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acschemneuro.4c00089","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
A Snake Venom Peptide and Its Derivatives Prevent Aβ42 Aggregation and Eliminate Toxic Aβ42 Aggregates In Vitro
Over a century has passed since Alois Alzheimer first described Alzheimer’s disease (AD), and since then, researchers have made significant strides in understanding its pathology. One key feature of AD is the presence of amyloid-β (Aβ) peptides, which form amyloid plaques, and therefore, it is a primary target for treatment studies. Naturally occurring peptides have garnered attention for their potential pharmacological benefits, particularly in the central nervous system. In this study, nine peptide derivatives of Crotamine, a polypeptide from Crotalus durissus terrificus Rattlesnake venom, as well as one d-enantiomer, were evaluated for their ability to modulate Aβ42 aggregation through various assays such as ThT, QIAD, SPR, and sFIDA. All tested peptides were able to decrease Aβ42 aggregation and eliminate Aβ42 aggregates. Additionally, all of the peptides showed an affinity for Aβ42. This study is the first to describe the potential of crotamine derivative peptides against Aβ42 aggregation and to identify a promising d-peptide that could be used as an effective pharmacological tool against AD in the future.
期刊介绍:
ACS Chemical Neuroscience publishes high-quality research articles and reviews that showcase chemical, quantitative biological, biophysical and bioengineering approaches to the understanding of the nervous system and to the development of new treatments for neurological disorders. Research in the journal focuses on aspects of chemical neurobiology and bio-neurochemistry such as the following:
Neurotransmitters and receptors
Neuropharmaceuticals and therapeutics
Neural development—Plasticity, and degeneration
Chemical, physical, and computational methods in neuroscience
Neuronal diseases—basis, detection, and treatment
Mechanism of aging, learning, memory and behavior
Pain and sensory processing
Neurotoxins
Neuroscience-inspired bioengineering
Development of methods in chemical neurobiology
Neuroimaging agents and technologies
Animal models for central nervous system diseases
Behavioral research